Progress of CD47 immune checkpoint blockade agents in anticancer therapy: a hematotoxic perspective

Volume: 148, Issue: 1, Pages: 1 - 14
Published: Oct 5, 2021
Abstract
CD47, a transmembrane protein, acts as a "do not eat me" signal that is overexpressed in many tumor cell types, thereby forming a signaling axis with its ligand signal regulatory protein alpha (SIRPα) and enabling the tumor cells to escape from macrophage-mediated phagocytosis. Several clinical trials with CD47 targeting agents are underway and have achieved impressive results preliminarily. However, hematotoxicity (particularly anemia) has...
Paper Details
Title
Progress of CD47 immune checkpoint blockade agents in anticancer therapy: a hematotoxic perspective
Published Date
Oct 5, 2021
Volume
148
Issue
1
Pages
1 - 14
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.